Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase
I/II
study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer:
NJLCG1402
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-15
DOI
10.1111/1759-7714.14149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non–small cell lung cancer
- (2021) Yasuto Yoneshima et al. Journal of Thoracic Oncology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial
- (2018) Akira Nakao et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
- (2017) Masaki Anzai et al. MEDICINE
- Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
- (2017) Eisaku Miyauchi et al. ONCOLOGIST
- The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
- (2017) Puyuan Xing et al. Oncotarget
- A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
- (2016) Yusuke Okuma et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301
- (2016) Shinya Sakata et al. LUNG CANCER
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer
- (2013) Miyako Satouchi et al. LUNG CANCER
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer
- (2011) Hajime Asahina et al. Clinical Lung Cancer
- Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice
- (2010) Nicolas Girard et al. Journal of Thoracic Oncology
- Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer
- (2008) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started